PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates

分组1 - PTC Therapeutics reported quarterly earnings of $0.2 per share, significantly beating the Zacks Consensus Estimate of a loss of $1.19 per share, and showing improvement from a loss of $1.39 per share a year ago, resulting in an earnings surprise of +116.81% [1] - The company achieved revenues of $211.01 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 20.17%, and up from $196.79 million in the same quarter last year [2] - PTC Therapeutics has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has increased approximately 50.5% since the beginning of the year, outperforming the S&P 500, which gained 16.5% [3] - The future performance of PTC Therapeutics' stock will depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.98 on revenues of $189.42 million, and for the current fiscal year, it is $7.72 on revenues of $1.72 billion [7] 分组3 - The Medical - Biomedical and Genetics industry, to which PTC Therapeutics belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The correlation between near-term stock movements and earnings estimate revisions suggests that tracking these revisions can provide insights into stock performance [5]